|Bid||5.170 x N/A|
|Ask||5.190 x N/A|
|Day's Range||5.090 - 5.600|
|52 Week Range||4.440 - 11.640|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 30, 2021|
|Forward Dividend & Yield||0.02 (0.25%)|
|Ex-Dividend Date||Jun 16, 2021|
|1y Target Est||N/A|
On August 30, 2021, Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2021 (the "Reporting Period"), revenue of the Group increased significantly to RMB1,026.5 million from RMB197.6 million for the corresponding period last year, representing a YoY increase of approximately 419.5%, gross profit increased substantially from RMB100.1 million for the corresponding period last year to RMB316.3 million, representing a YoY increase of 216.0%. The adjusted net profit of th
Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. Totient is a biotech company, harnessing human immune responses to identify novel antibodies and their therapeutic targets. This acquisition adds antibody and target discovery technology to AbSci's platform for therapeutic protein design and biomanufacturing optimization.
Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with biotech and IT industry partners to create a multi-party integrated industrial ecosystem, and realize AI's comprehensive empowerment in the field of biotechnology.